Medtronic Aktie
WKN DE: A14M2J / ISIN: IE00BTN1Y115
07.08.2024 14:31:01
|
Medtronic Announces FDA Approval Of Simplera CGM; Partners With Abbott To Expand CGM Options
(RTTNews) - Medtronic plc (MDT) announced the U.S. Food and Drug Administration approval for Simplera continuous glucose monitor, or CGM, the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs. The company said the recent FDA approval for Simplera CGM lays the groundwork for future submission of the updated InPen smart insulin pen app, which would facilitate integration with Simplera CGM, as a Smart MDI system.
Medtronic also announced a global partnership with Abbott to expand CGM options for people living with diabetes. The companies will collaborate on an integrated CGM based on Abbott's CGM platform. Abbott will supply Medtronic with a CGM that will work exclusively with Medtronic smart dosing devices and software across both automated insulin delivery and Smart MDI systems. These systems, including the Abbott-based CGM, will be sold exclusively by Medtronic. Medtronic expects the original equipment manufacturer agreement to be accretive to Diabetes revenue and neutral to Diabetes gross margin.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Abbott Laboratoriesmehr Nachrichten
24.04.25 |
NASDAQ Composite Index-Papier Abbott Laboratories-Aktie: So viel Gewinn hätte eine Abbott Laboratories-Investition von vor 10 Jahren eingebracht (finanzen.at) | |
23.04.25 |
NASDAQ Composite aktuell: NASDAQ Composite mittags in Grün (finanzen.at) | |
23.04.25 |
Optimismus in New York: NASDAQ Composite hebt zum Start ab (finanzen.at) | |
17.04.25 |
NASDAQ Composite Index-Titel Abbott Laboratories-Aktie: So viel Gewinn hätte ein Investment in Abbott Laboratories von vor 5 Jahren eingebracht (finanzen.at) | |
16.04.25 |
Verluste in New York: S&P 500 zeigt sich schlussendlich leichter (finanzen.at) | |
16.04.25 |
Schwacher Handel in New York: S&P 500 notiert am Mittwochnachmittag im Minus (finanzen.at) | |
16.04.25 |
NASDAQ-Handel NASDAQ Composite tiefrot (finanzen.at) | |
16.04.25 |
Börse New York: NASDAQ Composite präsentiert sich leichter (finanzen.at) |
Analysen zu Abbott Laboratoriesmehr Analysen
Aktien in diesem Artikel
Abbott Laboratories | 112,88 | -0,84% |
|
Medtronic PLC | 73,76 | -0,47% |
|